BATM Advanced Communications Ld BATM commences delivery of new COVID-19 tests (9137Y)
May 18 2021 - 01:00AM
UK Regulatory
TIDMBVC
RNS Number : 9137Y
BATM Advanced Communications Ld
18 May 2021
LEI: 213800FLQUB9J289RU66
18 May 2021
BATM Advanced Communications Limited
("BATM" or "the Group")
BATM commences delivery of saliva-based RT-PCR and new rapid
lateral flow COVID-19 tests
Italian Olympic Committee to use BATM's saliva COVID-19 test for
Tokyo Olympics
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time
technologies for networking solutions and medical laboratory
systems, announces that it has commenced delivery of two new
diagnostic tests for SARS-CoV-2 (COVID-19) and that the Italian
Olympic Committee intends to use the Group's saliva-based RT-PCR
test for the upcoming Olympic Games in Japan.
Saliva-based RT-PCR test
Further to the Group's announcement of 11 March 2021, BATM is
pleased to confirm that it has commenced supplying its test that
uses self-collected saliva samples to diagnose COVID-19 using the
RT-PCR technique.
The initial customers are public health authorities in Italy
that are using the tests in schools and elderly care homes where
there is a particular benefit for having a non-invasive sample
collection method without compromising diagnostic accuracy. The
provision of the tests is due to be expanded to several other
groups as production increases. The test is also due to be used by
the Italian Olympic Committee for the Olympic Games that are
scheduled to commence in Japan in July. This follows the Italian
Olympic Committee selecting two labs to provide testing for the
tournament, one of which uses only the Group's antigen RT-PCR kits
for COVID-19 testing, including the latest saliva-based test.
The test involves the individual spitting into a collector tube
rather than deep swabbing via the nose (nasopharyngeal swab) or
back of the throat (oropharyngeal swab). It is based on the Group's
antigen RT-PCR kit that has five (4+1) gene discovery capability,
which enables detection even with a very low viral load and has
100% accuracy for specificity and sensitivity. The test can be
administered without the need for trained healthcare workers in
full body personal protective equipment, offering advantages in
terms of speed of sample collection as well as lab processing and
being more cost effective than the RT-PCR process for standard
swab-based tests.
The Group is producing the test at its Adaltis facility in Rome,
Italy, which continues to increase manufacturing output. More
information can be found here .
Rapid lateral flow test
BATM is also pleased to announce the commercial launch of the
RAPiDgen(R) SARS-CoV-2 Ag test, which is an easy-to-use rapid test
that gives results in 8-15 minutes. The test detects SARS-CoV-2
antigens, using the lateral flow method, in samples collected with
a nasal (nostril) swab.
The test consists of a small self-contained device and a nasal
swab: after collecting a nasal secretion sample, the swab is placed
into an opening in the device, swirled and then the cap clicked to
a different direction. This compares with commonly available rapid
tests that require the individual to prepare the test by pouring a
buffer liquid into an extraction tube and, after swirling the
swabbed sample in the extraction tube, dropping liquid onto a test
strip. The RAPiDgen(R) SARS-CoV-2 Ag has undergone validation
testing by hospitals in Israel and Europe where it has demonstrated
sensitivity in excess of 95%.
The test has been developed by the Group's Adaltis subsidiary
and Gamidor Diagnostics ("Gamidor"). Gamidor is part of the Gamida
for Life B.V. group that is also a partner in the Group's Ador
Diagnostics associate company. The rapid test is being marketed
under the Adaltis brand and sold under a revenue-share agreement
with Gamidor. Production has commenced at Gamidor's facility in
Israel with initial deliveries being to public health authorities.
Negotiations are also underway to establish another production line
for this test in Europe.
Dr Zvi Marom, CEO of BATM, said:
"I am delighted with the performance of our diagnostic tests -
both commercially and medically. Our COVID-19 tests have
demonstrable advantages compared with others available in the
market in terms of accuracy, ease-of-use and cost
effectiveness.
"With the rollout of our saliva-based and rapid diagnostic kits,
we now offer a full range of tests that can provide a comprehensive
solution for tackling the pandemic. We continue to receive strong
demand for our COVID-19 tests - and, in particular, we are honoured
that the Italian Olympic Committee will be using our saliva tests
to support Italy's Olympic journey.
"At the same time, we expect this technology enabling precise
diagnoses using saliva samples to be applied to diseases beyond
COVID-19. It would be particularly beneficial for tests used to
quickly differentiate between illnesses to provide an accurate
diagnosis, such as our multi-pathogen respiratory test. We are also
continuing to work with our academic and business partners to
develop other innovative diagnostic solutions that we believe are
at the forefront of the battle against infectious disease.
"We are very proud of what we have achieved and very excited
about what's still to come, and we look forward to updating the
market in due course."
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Shore Capital
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)
Henry Willcocks (Corporate Broking) +44 20 7408 4050
Luther Pendragon
Harry Chathli, Claire Norbury +44 20 7618 9100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFFAELIDLIL
(END) Dow Jones Newswires
May 18, 2021 02:00 ET (06:00 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Mar 2023 to Mar 2024